image credit: kennejima / Flickr

Bristol Myers’ Opdivo wins landmark FDA nod as first I-O therapy for front-line stomach cancer

April 19, 2021


The stomach cancer field is littered with immunotherapy shipwrecks, but one has now safely sailed past the regulatory finish line.

Bristol Myers Squibb’s Opdivo, used in tandem with chemotherapy, won FDA approval for previously untreated gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma that are advanced or spread to other parts of the body. The go-ahead is for all tumors regardless of their expression of the PD-L1 marker.

Read More on FiercePharma